MUDr. Gvantsa KHARAISHVILI, Ph.D.
Telefon:
+420585639554
E-mail:
WWW:
Pracoviště:
Ústav klinické a molekulární patologie
Org. jednotka:
Lékařská fakulta
Adresa:
Dostavba Teoretických ústavů
Místnost:
5.533
Pracovní zařazení:
odborný asistent
VYBRANÉ PUBLIKACE
Mičková A., Eliáš M., Levková M., Kurfürstová D., Kharaishvili G., Überall I., Študent jr. V., Študent V., Drápela S., Souček K., Bouchal J.
Advantages and limitations of 3D organoids and ex vivo tumor tissue culture in personalized medicine for prostate cancer.
Klinicka Onkologie.
2022.
(ČLÁNEK)
ČLÁNEK
Goncharov AP., Elissaiou CD., Farzalla EBA., Akhvlediani G., Vashakidze N., Kharaishvili G.
Signalling pathways in a nutshell: from pathogenesis to therapeutical implications in prostate cancer.
ANNALS OF MEDICINE.
2025.
Goncharov AP., Vashakidze N., Kharaishvili G.
Epithelial-Mesenchymal Transition: A Fundamental Cellular and Microenvironmental Process in Benign and Malignant Prostate Pathologies.
Biomedicines.
2024.
Jelínková A., Kharaishvili G.
Melkersson-Rosenthalův syndrom v klinické praxi.
Dermatologie pro praxi.
2022.
Mičková A., Kharaishvili G., Kurfürstová D., Gachechiladze M., Král M., Vacek O., Pokryvková B., Mistrík M., Souček K., Bouchal J.
Skp2 and Slug Are Coexpressed in Aggressive Prostate Cancer and Inhibited by Neddylation Blockade.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
2021.
Gachechiladze M., Tichý T., Kolek V., Grygárková I., Klein J., Mgebrishvili G., Kharaishvili G., Janíková M., Smičková P., Čierna L., Pitson S., Maddelein M., Cuvillier O.
Sphingosine kinase-1 predicts overall survival outcomes in non-small cell lung cancer patients treated with carboplatin and navelbine.
Oncology Letters.
2019.
Kahounová Z., Kurfürstová D., Bouchal J., Kharaishvili G., Študent V.
The fibroblast surface markers FAP, anti-fibroblast, and FSP are expressed by cells of epithelial origin and may be altered during epithelial-to-mesenchymal transition.
Cytometry. Part A.
2018.
Remšík j., Binó L., Kahounová Z., Kharaishvili G., Bouchal J., Král M.
Trop-2 plasticity is controlled by epithelial-to-mesenchymal transition.
CARCINOGENESIS.
2018.
Vondálová Blanářová O., Šafaříková B., Herůdková J., Bouchal J., Kharaishvili G., Král M.
Cisplatin or LA-12 enhance killing effects of TRAIL in prostate cancer cells through Bid-dependent stimulation of mitochondrial apoptotic pathway but not caspase-10.
PLoS One.
2017.
Šimková D., Kharaishvili G., Slabáková E., Murray PG., Bouchal J.
Glycoprotein asporin as a novel player in tumour microenvironment and cancer progression.
Biomedical Papers-Olomouc.
2016.
Gachechiladze M., Škarda J., Janíková M., Mgebrishvili G., Kharaishvili G., Kolek V., Grygárková I., Klein J., Poprachová A., Arabuli M., Kolář Z.
Overexpression of filamin-A protein is associatd with aggressive phenotype and poor survival outcomes in NSCLC patients treated with platinum-based combination chemotherapy.
Neoplasma.
2016.
Janíková M., Žižková V., Škarda J., Kharaishvili G., Radová L., Kolář Z.
Prognostic significance of miR-23b in combination with P-gp, MRP and LRP/MVP expression in non-small cell lung cancer.
Neoplasma.
2016.
Luef B., Handle F., Kharaishvili G., Hager M., Rainer J., Janetschek G., Hruby S., Englberger C., Bouchal J., Santer F., Culig Z.
The AR/NCOA1 axis regulates prostate cancer migration by involvement of PRKD1.
Endocrine Related Cancer.
2016.
Šimková D., Kharaishvili G., Kořínková G., Oždian T., Suchánková-Kleplová T., Soukup T., Křupka M., Galandáková A., Džubák P., Janíková M., Navrátil J., Kahounová Z., Souček K., Bouchal J.
The dual role of asporin in breast cancer progression.
Oncotarget.
2016.
Bouchalová K., Svoboda M., Kharaishvili G., Vrbková J., Bouchal J., Trojanec R., Koudeláková V., Radová L., Cwiertka K., Hajdúch M., Kolář Z.
BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
Tumor Biology.
2015.
Slabáková E., Kharaishvili G., Smějová M., Pernicová Z., Suchánková T., Remšík J., Lerch S., Straková N., Bouchal J., Král M., Culig Z., Kozubík A., Souček K.
Opposite regulation of MDM2 and MDMX expression in acquisition of mesenchymal phenotype in benign and cancer cells.
Oncotarget.
2015.
Kharaishvili G., Šimková D., Bouchalová K., Gachechiladze M., Narsia N., Bouchal J.
The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance.
Cancer Cell International.
2014.
Pernicová Z., Slabáková E., Fedr R., Šimečková Š., Jaroš J., Suchánková T., Bouchal J., Kharaishvili G., Král M., Kozubík A., Souček K.
The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells.
Molecular Cancer.
2014.
Bouchalová K., Kharaishvili G., Bouchal J., Vrbková J., Megová M., Hlobilková A.
Triple negative breast cancer-BCL2 in prognosis and prediction.
Current Drug Targets.
2014.
PERNICOVÁ Z., SLABÁKOVÁ E., KHARAISHVILI G., BOUCHAL J., KRÁL M.
Androgen Depletion Induces Senescence in Prostate Cancer Cells through Down-regulation of Skp21,2.
Neoplasia.
2011.
KHARAISHVILI G., ČÍŽKOVÁ M., BOUCHALOVÁ K., MGEBRISHVILI G., KOLÁŘ Z., BOUCHAL J.
Collagen triple helix repeat containing 1 protein periostin and versican in primary and metastatic breast cancer: an immunohistochemical study.
Journal of Clinical Pathology.
2011.
KHARAISHVILI G., ŠIMKOVÁ D., Makharoblidze E., TRTKOVÁ K., KOLÁŘ Z., BOUCHAL J.
WNT signaling in prostate development and carcinogenesis.
Biomedical Papers-Olomouc.
2011.
KAPITOLA V KNIZE
Kharaishvili G., Kacheishvili M., Akhvlediani G.
BRCA Gene Mutations and Prostate Cancer.
BRCA1 and BRCA2 Mutations - Diagnostic and Therapeutic Implications.
2023.
Kharaishvili G.
Extracellular Matrix in Tumor Angiogenesis.
Tumor Angiogenesis and Modulators.
2022.
ABSTRAKT
Kharaishvili G., Kolář Z., Bouchal J., Král M.
Tertiary Gleason, grade groups and biomaekers for prostate cancer risk stratification: models and algorithms.
Virchows Archiv.
2019.
Kolář Z., Šimková D., Kharaishvili G., Kořínková G., Bouchal J.
Glycoprotein asporin in associated with progression of high-grade but not of low-grade breast cancer.
Virchows Archiv.
2017.
Šimková D., Kharaishvili G., Bouchal J.
Asporin ovlivňuje migrační a invazní schopnosti nádorových buněk prsu.
Program a abstrakty na Dni molekulovej patológie.
2015.
Bouchalová K., Svoboda M., Kharaishvili G., Vrbková J., Bouchal J., Trojanec R., Koudeláková V., Cwiertka K., Hajdúch M.
BRCA-mutation status combined with BCL2 protein in prediction of relapse in triple-negative breast cancer (TNBC) treated with adjuvant anthracycline-based chemotherapy.
Klinická onkologie.
2015.
Gachechiladze M., Škarda J., Mgebrishvili G., Kharaishvili G., Kolek V., Klein J., Poprachová A., Arabuli M., Kolář Z.
Expression levels of Filamin A protein predict survival outcomes in non-small cell lung cancer patients treated with Carboplatin and Navelbine.
Virchows Archiv.
2015.
Bouchalová K., Svoboda M., Kharaishvili G., Vrbková J., Slavkovský R., Bouchal J., Navrátil J., Koudeláková V., Trojanec R., Cwiertka K., Hajdúch M., Kolář Z.
Triple negative breast cancer (TNBC): BCL11A gene status in prediction of survival in patients treated with anthracycline-based chemotherapy.
XI. Diagnostic, Predictive and Experimental Oncology Days: Abstract Book.
2015.
Bouchalová K., Svoboda M., Kharaishvili G., Vrbková J., Radová L., Bouchal J., Trojanec R., Koudeláková V., Cwiertka K., Hajdúch M., Kolář Z.
BRCA-mutation status combined with BCL2 protein in prediction of relapse in triple-negative breast cancer (TNBC) treated with adjuvant anthracycline-based chemotherapy.
Abstract Book, X. Diagnostic, Predictive and Experimental Oncology Days.
2014.
Škarda J., Tichý T., Kharaishvili G., Kolář Z., Grygárková I., Kolek V.
Prediktivní markery v cílené léčbě karcinomů plic z pohledu patologa.
Programme and Abstract Book.
2014.
Bouchalová K., Svoboda M., Kharaishvili G., Radová L., Bouchal J., Trojanec R., Koudeláková V., Hajdúch M., Cwiertka K., Kolář Z.
BCL2 in triple-negative breast cancer treated with adjutant anthracycline-based chemotherapy.
Sborník abstrakt: Konference Chemické biologie a genetiky.
2013.
Bouchalová K., Kharaishvili G., Svoboda M., Radová L., Bouchal J., Trojanec R., Koudelaková V., Hajdúch M., Cwiertka K., Kolář M.
BCL2 in triple-negative breast cancer treated with adjuvant anthracycline-based chemotherapy – independent predictor of outcome.
sborník abstrakt - XXXVII. Brno´s Oncology Days.
2013.
Koudeláková V., Radová L., Svoboda M., Wei W., Kharaishvili G., Bouchal J., Trojanec R., Hajdúch M., Kolář Z., Bouchalová K.
Copy number changes in triple-negative breast cancer: New molecular targets.
Journal of Clinical Oncology.
2013.
Bouchalová K., Kharaishvili G., Svoboda M., Radová L., Bouchal J., Trojanec R., Koudeláková V., Hajdúch M., Kolář Z.
EGFR gene/protein and survival in triple negative breast carcinoma (TNBC).
Breakthrough Triple Negative Breast Cancer Conference.
2013.
Bouchalová K., Svoboda M., Kharaishvili G., Radová L., Bouchal J., Trojanec R., Koudeláková V., Hajdúch M., Cwiertka K., Kolář Z.
BCL2 as a predictive marker in triple-negative breast cancer treated with adjuvant anthracycline-based chemotherapy.
Optics Communications.
2012.
BOUCHALOVÁ K., Čížková M., Trojanec R., Koudeláková V., Radová L., Fürstová J., MELICHAR B., CWIERTKA K., KHARAISHVILI G., Kolář Z., Hajdúch M.
BCL2 is a predictive marker of adjuvant CMF regimen in triple negative breast cancer (TNBC) patiens.
Edukační sborník.
2012.
Bouchalová K., Svoboda M., Kharaishvili G., Radová L., Bouchal J., Trojanec R., Koudeláková V., Hajdúch M., Cwiertka K., Kolář Z.
BCL2 protein in prediction of relapse in triple-negative breast cancer (TNBC) treated with adjuvant anthracycline-based chemotherapy.
Journal of Clinical Oncology - suplement.
2012.
Kharaishvili G., Čížková M., Bouchalová K., Sedláková E., Kolář Z., Bouchal J.
Asporin modulates tissue microenvironment, invasive growth and bone metastasis of breast cancer.
Programme and Abstract Book.
2011.
BOUCHALOVÁ K., ČÍŽKOVÁ M., TROJANEC R., KOUDELÁKOVÁ V., FÜRSTOVÁ J., MELICHAR B., CWIERTKA K., KHARAISHVILI G., KOLÁŘ Z., HAJDÚCH M.
BCL2 is predictive marker of adjutant CMF regimen in triple-negative breast cancer patients.
Breast Cancer Research (print).
2011.
Kharaishvili G., Čížková M., Bouchalová K., Sedláková E., Mgebrishvili G., Kolář Z., Bouchal J.
Collagen triple helix repeat containing 1 protein in primary and metastatic breast cancer.
Programme and Abstract Book.
2011.
KHARAISHVILI G., ŠIMKOVÁ D., ČÍŽKOVÁ M., BOUCHALOVÁ K., MGEBRISHVILI G., KOLÁŘ Z., BOUCHAL J.
Nestin and collagen triple helix repeat containing 1 in triple negative breast cancer.
Onkologie.
2011.
Šimková D., Kharaishvili G., Čížková M., Bouchalová K., Kolář Z., Bouchal J.
Proteoglykan asporin a jeho vliv na invazivní růst karcinomu prsu.
Edukační sborník Brněnských onkologických dnů.
2011.
BOUCHALOVÁ K., ČÍŽKOVÁ M., TROJANEC R., KOUDELÁKOVÁ V., MLČOCHOVÁ S., RADOVÁ L., MELICHAR B., CWIERTKA K., KHARAISHVILI G., KOLÁŘ Z., HAJDÚCH M.
Triple negative breast carcinoma (TNBC) - challenge for translational oncology: our results of chromosome 17 and BCL2 protein assessment.
Optics Communications.
2011.
Bouchal J., Šimková D., Kharaishvili G.
Asporin Is Associated with Invasive Growth and Bone Metastasis Breast Cancer.
Cancer Research.
2010.
Kharaishvili G., Čížková M., Sedláková E., Kolář Z., Bouchal J.
Immunohistochemical analysis of collagen triple helix containing 1 protein in breast cancer patients.
Optics Communications.
2010.
Pernicová Z., Slabáková E., Kharaishvili G., Bouchal J., Král M.
Role of Skp2 in senescence and neuroendocrine transdifferentiation induced by androgen depletion in prostate cacer cells.
Advances in Molecular and Cancer Biology.
2010.
PŘEDNÁŠKA NEBO POSTER
Bouchalová K., Svoboda M., Kharaishvili G., Radová L., Bouchal J., Trojanec R., Koudeláková V., Hajdúch M., Cwiertka K., Kolář Z.
BCL2 in triple-negative breast cancer treated with adjutant anthracycline-based chemotherapy.
2013.
Bouchalová K., Svoboda M., Kharaishvili G., Radová L., Bouchal J., Trojanec R., Koudeláková V., Hajdúch M., Cwiertka K., Kolář Z.
BCL2 in triple-negative breast cancer treated with adjuvant anthracycline-based chemotherapy-independent predictor of outcome.
2013.
Koudeláková V., Radová L., Svoboda M., Wei W., Kharaishvili G., Bouchal J., Trojanec R., Hajdúch M., Kolář Z., Bouchalová K.
Copy number changes in triple-negative breast cancer: New molecular targets.
2013.
Bouchalová K., Kharaishvili G., Svoboda M., Radová L., Bouchal J., Trojanec R., Koudeláková V., Hajdúch M., Kolář Z.
EGFR gene/protein and survival in triple negative breast carcinoma (TNBC).
2013.
Uživatel nepovolil zobrazení dat v Portále UP.